Navigation Links
Clarient Reports 2009 Third Quarter; Nine Month Results
Date:11/3/2009

ded September 30, 2009, loss from continuing operations before income taxes was $4.9 million compared to a loss from continuing operations before income taxes of $7.4 million for the nine months ended September 30, 2008.

Clarient's net loss for the third quarter 2009 was $3.2 million, or ($0.04) per share applicable to common stockholders. In the third quarter of 2008, the Company reported a net loss of $2.2 million, or ($0.03) per share applicable to common stockholders.

For the nine months ended September 30, 2009 and 2008, the net loss was $3.4 million and $7.4 million, respectively. Net loss per share applicable to common stockholders for the nine months ended September 30, 2009 and 2008 was ($0.10) and ($0.10), respectively.

Adjusted EBITDA (defined below) for the 2009 third quarter was a negative $1.6 million, compared to adjusted EBITDA of $1.4 million in the third quarter of 2008. For the 2009 nine-month period, adjusted EBITDA was $3.1 million, compared to adjusted EBITDA of $2.6 million in the prior year period, an increase of 19 percent.

Operating expenses were $14.7 million for the third quarter of 2009, compared to $10.2 million in the same quarter of 2008. For the first nine months of 2009, operating expenses totaled $40.5 million, compared to $29.0 million in the year-earlier period. The increase in operating expenses in the third quarter of 2009 versus the comparable period in 2008 was largely related to additional sales and marketing personnel costs and investment in our information technology infrastructure.

At September 30, 2009, Clarient's cash and cash equivalents totaled $8.1 million compared with $1.8 million at December 31, 2008.

Ray Land, Senior Vice President and Chief Financial Officer, said, "In the long term we will greatly benefit from the changes we made this quarter. The new information will allow us to better estimate our expected reimbursement rates, give us
'/>"/>

SOURCE Clarient, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Clarient to Present at Noble Financials 5th Annual Equity Conference on Tuesday, June 9th
2. Clarient Completes Second Tranche of Private Placement of Convertible Preferred Stock With Oak Investment Partners
3. Clarient Granted Exclusive License to Commercialize Breast Cancer Biomarker by Indiana University Research and Technology Corporation
4. Clarient Reports Strong Revenue Increase for Fourth Quarter and Full-Year 2008
5. [video] Ronald Andrews, CEO of Clarient, Inc. Discusses Agreement With University of Pennsylvania School of Medicine on WallSt.nets 3-Minute Press Show
6. Clarient Names Raymond J. Land Senior Vice President and Chief Financial Officer
7. Jim Agnello to Resign as Clarient Chief Financial Officer
8. Clarient Announces Fourth Quarter and Year-End 2007 Financial Results
9. CombiMatrix and Clarient Collaborate to Market, Sell Novel Genomics-Based Test for Chronic Lymphotic Leukemia (CLL)
10. Clarient to Commercialize Novel Breast Cancer Profile
11. Clarient CEO Ron Andrews to Participate in OneMedPlace Emerging Healthcare Technologies Finance Forum

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)... The New York investment bank KT...:NEU) has agreed an AU$6.7 mil convertible note pr.... The private placement was arranged by KTA Capita...r. , New York (PRWEB) Nov...ent bank KTA Capital, LLC ("KTA Capital"...
(Date:11/24/2009)... Health care employment grew b...e only one to show consistent growth during the U....tals remain in trouble, and health systems are com...nnel, instead of just administrators. , ... care employment continued growing in October desp...
(Date:11/24/2009)..., SEATTLE, Nov. 24 Blue Marble ...the Odessa Public Development Authority (OPDA) wer...s Community Economic Revitalization Board (CERB) i...ate,s first specialty biochemical biorefinery in L...ignificantly speed the development of our biorefin...
(Date:11/24/2009)... , SAN DIEGO, Nov. 24, 2009 /PRNewswire-Firs...NA ) announced today that the company is schedul...lth Care Conference on December 1, 2009 at 11:30 a...ew York Palace Hotel in New York City. Jack Lief, ...scheduled to provide an overview of the company, i...
Breaking Biology Technology:KTA Capital Arranges an AU$6.7 Million Private Placement by Neuren Pharmaceuticals 2The MedZilla Report for October 2009 - Health Care Employment Grows Again in October Even As Clinics, Specialty Centers Close 2The MedZilla Report for October 2009 - Health Care Employment Grows Again in October Even As Clinics, Specialty Centers Close 3The MedZilla Report for October 2009 - Health Care Employment Grows Again in October Even As Clinics, Specialty Centers Close 4Blue Marble Energy, OPDA Awarded $2M by WA's Community Economic Revitalization Board 2Arena Pharmaceuticals to Present at the Piper Jaffray 21st Annual Health Care Conference 2Arena Pharmaceuticals to Present at the Piper Jaffray 21st Annual Health Care Conference 3
.../ - Angiotech Pharmaceuticals,Inc. (NASDAQ: ANPI ...,medical device company, announced today that the ...dical Inc.,s Zilver(R) PTX(TM) drug-eluting,periph...treated in February,2008. The Zilver PTX is the wo...rial disease (PAD) and was recently released for s...
...tists in fields,as diverse as pharmaceutical resea...e Olympus FluoroPoint(TM) single molecule fluoresc...alysis. Already in use in,scores of laboratories a...vity, low sample volumes, flexibility and ease of ...creening and research laboratories., FluoroPoint ...
...ernational, Inc.,(Quest) announced they will show ...ing an Apple Mac system, OsiriX and the Totoku, ME... for Imaging Informatics in,Medicine (SIIM), to be...nstrating the imaging breakthrough using the Apple...al, LCD displays. The,ME551i2 is a 21.3-inch, 5 me...
Other Biology Technology:Angiotech announces commercial launch of Cook Medical's Zilver(R) PTX(TM) drug-eluting peripheral stent in New Zealand 2Angiotech announces commercial launch of Cook Medical's Zilver(R) PTX(TM) drug-eluting peripheral stent in New Zealand 3Angiotech announces commercial launch of Cook Medical's Zilver(R) PTX(TM) drug-eluting peripheral stent in New Zealand 4Olympus FluoroPoint(TM) System Provides High-Sensitivity Single Molecule and Protein Interaction Analysis for Screening and Research 2Olympus FluoroPoint(TM) System Provides High-Sensitivity Single Molecule and Protein Interaction Analysis for Screening and Research 3Quest International Announces They Will be First in US to Exhibit True 12-Bit Grayscale Mammographic Images 2
(Date:11/24/2009)...s fish food is a matter of debate. A high-profile ...st 50 percent of their carbon from trees and leave...estrial and aquatic ecosystems. , But new resear... not likely to be true. Algae provide a much riche...to research published this week in the Proceeding...
(Date:11/23/2009)... The community-associated strain of the deadly su... to most common antibioticsposes a far greater hea... way into hospitals, according to a study in the D..., The new threat is easily picked up in fitness ...increased the overall burden of MRSA within hospit...
(Date:11/23/2009)...- More than 160 participants gathered this week fo...ES INITIATIVE conference. This year,s topic, "Synt...eers, and medical researchers to explore the engin...the emerging field of synthetic biology. , Bonni...inceton University and this year,s conference chai...
Breaking Biology News(10 mins):Fish food fight: Fish don't eat trees after all, says new study 2Fish food fight: Fish don't eat trees after all, says new study 3New study finds MRSA on the rise in hospital outpatients 2Synthetic biology offers new opportunities for interdisciplinary collaboration 2Swine Flu Now Reported in All 50 States 47547 1Swine Flu Now Reported in All 50 States 47547 2Swine Flu Now Reported in All 50 States 47547 3Swine Flu Now Reported in All 50 States 47547 4Swine Flu Now Reported in All 50 States 47547 5Swine Flu Now Reported in All 50 States 47547 6Swine Flu Now Reported in All 50 States 47547 7Swine Flu Now Reported in All 50 States 47547 8Swine Flu Now Reported in All 50 States 47547 9Swine Flu Now Reported in All 50 States 47547 10Swine Flu Now Reported in All 50 States 47547 11Research Finds New Crop of Breast Cancer Genes 47543 1Research Finds New Crop of Breast Cancer Genes 47543 2New Study Documents High Prevalence of Serious Mental Illnesses Among Nations Jail Populations 47540 1New Study Documents High Prevalence of Serious Mental Illnesses Among Nations Jail Populations 47540 2
...gnized turfgrass researcher from the University of...ives in sun, but also produces healthy turf in are... for healthy Bermuda grass. , The new Bermudagras...Foundation, Inc., to New Concept Turf, will soon b...evelopers for recreational facilities, sports comp...
...s, Professor of Biology at Georgia State Universit...the National Institutes of Health to further resea...The prestigious Method to Extend Research in Time ...tes and Kidney Diseases will provide long-term for...op between fat cells and the brain, which Bartness...
...cently acquired a hyperspectral scanner from the F...ain and which will enable the study in depth of ap...h wavelengths that are not visible. , This scanne...grates all the elements required for acquiring an ...00nm, known as SWIR (short-wavelength infrared). ,...
Other Biology News:Researcher garners major award from NIH for further exploration into the mechanisms of obesity 2
Anti-Phosphotyrosine IgG Monoclonal Antibody, Alkaline Phosphatase Conjugated, Clone AD548 from Assay Designs/Stressgen Bioreagents
Rabbit Anti-Myosin VIIa Polyclonal Antibody, Unconjugated from Abcam
Mouse Anti-LAP2 Monoclonal Antibody, Unconjugated, Clone 6E10 from Abcam
BD FACSCanto flow cytometer from BD Biosciences - Immunocytometry Systems
Biology Products: